Advanced search
Publication Cover
Future Medicinal Chemistry Volume 2, 2010 - Issue 3
Submit an article Journal homepage
242
Views
0
CrossRef citations to date
0
Altmetric
Review

Targeted Probes for Cardiovascular MRI

Ritika UppalAthinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA02129, USAView further author information
&
Peter CaravanAthinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA02129, USACorrespondence[email protected]
View further author information
Pages 451-470 | Published online: 17 Mar 2010

Bibliography

  • Caravan P , LaufferRB. Contrast agents: basic principles. In: Clinical Magnetic Resonance Imaging. Edelman RR, Hesselink JR, Zlatkin MB, Crues JV (Eds). Saunders, Philadelphia, USA, 357–375 (2005).
  • Thomson LE , KimRJ, JuddRM. Magnetic resonance imaging for the assessment of myocardial viability.J. Magn. Reson. Imaging19(6), 771–788 (2004).
  • Goyen M , EdelmanM, PerreaultPet al. MR angiography of aortoiliac occlusive disease: a Phase III study of the safety and effectiveness of the blood-pool contrast agent MS-325. Radiology 236(3), 825–833 (2005).
  • Caravan P , ParigiG, ChasseJMet al. Albumin binding, relaxivity, and water exchange kinetics of the diastereoisomers of MS-325, a gadolinium(III)-based magnetic resonance angiography contrast agent. Inorg. Chem. 46(16), 6632–6639 (2007).
  • Eldredge HB , SpillerM, ChasseJM, GreenwoodMT, CaravanP. Species dependence on plasma protein binding and relaxivity of the gadolinium-based MRI contrast agent MS-325.Invest. Radiol.41(3), 229–243 (2006).
  • Weissleder R , MahmoodU. Molecular imaging.Radiology219(2), 316–333. (2001).
  • Sosnovik DE , NahrendorfM, WeisslederR. Molecular magnetic resonance imaging in cardiovascular medicine.Circulation115(15), 2076–2086 (2007).
  • Nahrendorf M , JafferFA, KellyKAet al. Noninvasive vascular cell adhesion molecule-1 imaging identifies inflammatory activation of cells in atherosclerosis. Circulation 114(14), 1504–1511 (2006).
  • Jaffer FA , WeisslederR. Seeing within: molecular imaging of the cardiovascular system.Circ. Res.94(4), 433–445 (2004).
  • Sosnovik DE . Molecular imaging in cardiovascular magnetic resonance imaging: current perspective and future potential.Top. Magn. Reson. Imaging19(1), 59–68 (2008).
  • Laurent S , ForgeD, PortMet al. Magnetic iron oxide nanoparticles: synthesis, stabilization, vectorization, physicochemical characterizations, and biological applications. Chem. Rev. 108(6), 2064–2110 (2008).
  • McCarthy JR , WeisslederR. Multifunctional magnetic nanoparticles for targeted imaging and therapy.Adv. Drug Deliv. Rev.60(11), 1241–1251 (2008).
  • Sosnovik DE , NahrendorfM, WeisslederR. Magnetic nanoparticles for MR imaging: agents, techniques and cardiovascular applications.Basic Res. Cardiol.103(2), 122–130 (2008).
  • Kraitchman DL , HeldmanAW, AtalarEet al. In vivo magnetic resonance imaging of mesenchymal stem cells in myocardial infarction. Circulation107(18), 2290–2293 (2003).
  • Kraitchman DL , TatsumiM, GilsonWDet al. Dynamic imaging of allogeneic mesenchymal stem cells trafficking to myocardial infarction. Circulation 112(10), 1451–1461 (2005).
  • Thorek DL , ChenAK, CzuprynaJ, TsourkasA. Superparamagnetic iron oxide nanoparticle probes for molecular imaging.Ann. Biomed. Eng.34(1), 23–38 (2006).
  • Korosoglou G , WeissRG, KedziorekDAet al. Noninvasive detection of macrophage-rich atherosclerotic plaque in hyperlipidemic rabbits using ‘positive contrast’ magnetic resonance imaging. J. Am. Coll. Cardiol. 52(6), 483–491 (2008).
  • Reynolds PR , LarkmanDJ, HaskardDOet al. Detection of vascular expression of E-selectin in vivo with MR imaging. Radiology 241(2), 469–476 (2006).
  • Flacke S , FischerS, ScottMJet al. Novel MRI contrast agent for molecular imaging of fibrin: implications for detecting vulnerable plaques. Circulation 104(11), 1280–1285 (2001).
  • Johansson LO , BjornerudA, AhlstromHK, LaddDL, FujiiDK. A targeted contrast agent for magnetic resonance imaging of thrombus: implications of spatial resolution.J. Magn. Reson. Imaging13(4), 615–618 (2001).
  • Sosnovik DE , SchellenbergerEA, NahrendorfMet al. Magnetic resonance imaging of cardiomyocyte apoptosis with a novel magneto-optical nanoparticle. Magn. Reson. Med. 54(3), 718–724 (2005).
  • McAteer MA , SchneiderJE, AliZAet al. Magnetic resonance imaging of endothelial adhesion molecules in mouse atherosclerosis using dual-targeted microparticles of iron oxide. Arterioscler. Thromb. Vasc. Biol. 28(1), 77–83 (2008).
  • von zur Muhlen C , von ElverfeldtD, MoellerJAet al. Magnetic resonance imaging contrast agent targeted toward activated platelets allows in vivo detection of thrombosis and monitoring of thrombolysis. Circulation118(3), 258–267 (2008).
  • Fuster V , MorenoPR, FayadZA, CortiR, BadimonJJ. Atherothrombosis and high-risk plaque: part I: evolving concepts.J. Am. Coll. Cardiol.46(6), 937–954 (2005).
  • Shah PK . Pathophysiology of coronary thrombosis: role of plaque rupture and plaque erosion.Prog. Cardiovasc. Dis.44(5), 357–368 (2002).
  • Virmani R , BurkeAP, KolodgieFD, FarbA. Vulnerable plaque: the pathology of unstable coronary lesions.J. Interv. Cardiol.15(6), 439–446 (2002).
  • Libby P . Inflammation in atherosclerosis.Nature420(6917), 868–874 (2002).
  • Lanza GM , AbendscheinDR, YuXet al. Molecular imaging and targeted drug delivery with a novel, ligand-directed paramagnetic nanoparticle technology. Acad. Radiol. 9(Suppl. 2), S330–S331 (2002).
  • Trivedi RA , U-King-ImJM, GravesMJet al. In vivo detection of macrophages in human carotid atheroma: temporal dependence of ultrasmall superparamagnetic particles of iron oxide-enhanced MRI. Stroke35(7), 1631–1635 (2004).
  • Kooi ME , CappendijkVC, CleutjensKBet al. Accumulation of ultrasmall superparamagnetic particles of iron oxide in human atherosclerotic plaques can be detected by in vivo magnetic resonance imaging. Circulation 107(19), 2453–2458 (2003).
  • Jaffer FA , NahrendorfM, SosnovikD, KellyKA, AikawaE, WeisslederR. Cellular imaging of inflammation in atherosclerosis using magnetofluorescent nanomaterials.Mol. Imaging5(2), 85–92 (2006).
  • Weissleder R , KellyK, SunEY, ShtatlandT, JosephsonL. Cell-specific targeting of nanoparticles by multivalent attachment of small molecules.Nat. Biotechnol.23(11), 1418–1423 (2005).
  • Stuber M , GilsonWD, ScharMet al. Positive contrast visualization of iron oxide-labeled stem cells using inversion-recovery with ON-resonant water suppression (IRON). Magn. Reson. Med. 58(5), 1072–1077 (2007).
  • Farrar CT , DaiG, NovikovMet al. Impact of field strength and iron oxide nanoparticle concentration on the linearity and diagnostic accuracy of off-resonance imaging. NMR Biomed. 21(5), 453–463 (2008).
  • Tsourkas A , Shinde-PatilVR, KellyKAet al. In vivo imaging of activated endothelium using an anti-VCAM-1 magnetooptical probe. Bioconjug. Chem.16(3), 576–581 (2005).
  • Kelly KA , AllportJR, TsourkasA, Shinde-PatilVR, JosephsonL, WeisslederR. Detection of vascular adhesion molecule-1 expression using a novel multimodal nanoparticle.Circ. Res.96(3), 327–336 (2005).
  • Kang PM , IzumoS. Apoptosis and heart failure: a critical review of the literature.Circ. Res.86(11), 1107–1113 (2000).
  • Weissleder R , LeeAS, KhawBA, ShenT, BradyTJ. Antimyosin-labeled monocrystalline iron oxide allows detection of myocardial infarct: MR antibody imaging.Radiology182(2), 381–385 (1992).
  • Port M , IdeeJM, MedinaC, RobicC, SabatouM, CorotC. Efficiency, thermodynamic and kinetic stability of marketed gadolinium chelates and their possible clinical consequences: a critical review.Biometals21(4), 469–490 (2008).
  • Rofsky NM , SherryAD, LenkinskiRE. Nephrogenic systemic fibrosis: a chemical perspective.Radiology247(3), 608–612 (2008).
  • Thomsen HS , MarckmannP. Extracellular Gd-CA: differences in prevalence of NSF.Eur. J. Radiol.66(2), 180–183 (2008).
  • Lancelot E , AmirbekianV, BriggerIet al. Evaluation of matrix metalloproteinases in atherosclerosis using a novel noninvasive imaging approach. Arterioscler. Thromb. Vasc. Biol. 28(3), 425–432 (2008).
  • Amirbekian V , AguinaldoJG, AmirbekianSet al. Atherosclerosis and matrix metalloproteinases: experimental molecular MR imaging in vivo. Radiology 251(2), 429–438 (2009).
  • Helm PA , CaravanP, FrenchBAet al. Postinfarction myocardial scarring in mice: molecular MR imaging with use of a collagen-targeting contrast agent. Radiology 247(3), 788–796 (2008).
  • Caravan P , DasB, DumasSet al. Collagen-targeted MRI contrast agent for molecular imaging of fibrosis. Angew. Chem. Int. Ed. Engl. 46(43), 8171–8173 (2007).
  • Caravan P , DasB, DengQet al. A lysine walk to high relaxivity collagen-targeted MRI contrast agents. Chem. Commun. (Camb.) (4), 430–432 (2009).
  • Corti R , FarkouhME, BadimonJJ. The vulnerable plaque and acute coronary syndromes.Am. J. Med.113(8), 668–680 (2002).
  • Botnar RM , PerezAS, WitteSet al. In vivo molecular imaging of acute and subacute thrombosis using a fibrin-binding magnetic resonance imaging contrast agent. Circulation109(16), 2023–2029 (2004).
  • Overoye-Chan K , KoernerS, LoobyRJet al. EP-2104R: a fibrin-specific gadolinium-based MRI contrast agent for detection of thrombus. J. Am. Chem. Soc. 130(18), 6025–6039 (2008).
  • Sirol M , AguinaldoJG, GrahamPBet al. Fibrin-targeted contrast agent for improvement of in vivo acute thrombus detection with magnetic resonance imaging. Atherosclerosis 182(1), 79–85 (2005).
  • Spuentrup E , KatohM, BueckerAet al. Molecular MR imaging of human thrombi in a swine model of pulmonary embolism using a fibrin-specific contrast agent. Invest. Radiol. 42(8), 586–595 (2007).
  • Spuentrup E , KatohM, WiethoffAJet al. Molecular magnetic resonance imaging of pulmonary emboli with a fibrin-specific contrast agent. Am. J. Respir. Crit. Care Med. 172(4), 494–500 (2005).
  • Spuentrup E , FaustenB, KinzelSet al. Molecular magnetic resonance imaging of atrial clots in a swine model. Circulation 112(3), 396–399 (2005).
  • Spuentrup E , BueckerA, KatohMet al. Molecular magnetic resonance imaging of coronary thrombosis and pulmonary emboli with a novel fibrin-targeted contrast agent. Circulation 111(11), 1377–1382 (2005).
  • Botnar RM , BueckerA, WiethoffAJet al. In vivo magnetic resonance imaging of coronary thrombosis using a fibrin-binding molecular magnetic resonance contrast agent. Circulation110(11), 1463–1466 (2004).
  • Spuentrup E , BotnarRM, WiethoffAJet al. MR imaging of thrombi using EP-2104R, a fibrin-specific contrast agent: initial results in patients. Eur. Radiol. 18(9), 1995–2005 (2008).
  • Nair SA , KolodziejAF, BholeG, GreenfieldMT, McMurryTJ, CaravanP. Monovalent and bivalent fibrin-specific MRI contrast agents for detection of thrombus.Angew. Chem. Int. Ed. Engl.47(26), 4918–4921 (2008).
  • Morawski AM , WinterPM, YuXet al. Quantitative ‘magnetic resonance immunohistochemistry’ with ligand-targeted (19)F nanoparticles. Magn. Reson. Med. 52(6), 1255–1262 (2004).
  • Sanders HM , StrijkersGJ, MulderWJet al. Morphology, binding behavior and MR-properties of paramagnetic collagen-binding liposomes. Contrast Media Mol. Imaging 4(2), 81–88 (2009).
  • Amirbekian V , LipinskiMJ, Briley-SaeboKCet al. Detecting and assessing macrophages in vivo to evaluate atherosclerosis noninvasively using molecular MRI. Proc. Natl Acad. Sci. USA 104(3), 961–966 (2007).
  • Mulder WJ , DoumaK, KoningGAet al. Liposome-enhanced MRI of neointimal lesions in the ApoE-KO mouse. Magn. Reson. Med. 55(5), 1170–1174 (2006).
  • Winter PM , MorawskiAM, CaruthersSDet al. Molecular imaging of angiogenesis in early-stage atherosclerosis with α-(v)-β-3-integrin-targeted nanoparticles. Circulation 108(18), 2270–2274 (2003).
  • Lipinski MJ , AmirbekianV, FriasJCet al. MRI to detect atherosclerosis with gadolinium-containing immunomicelles targeting the macrophage scavenger receptor. Magn. Reson. Med. 56(3), 601–610 (2006).
  • Briley-Saebo KC , ShawPX, MulderWJet al. Targeted molecular probes for imaging atherosclerotic lesions with magnetic resonance using antibodies that recognize oxidation-specific epitopes. Circulation 117(25), 3206–3215 (2008).
  • Meding J , UrichM, LichaKet al. Magnetic resonance imaging of atherosclerosis by targeting extracellular matrix deposition with gadofluorine M. Contrast Media Mol. Imaging 2(3), 120–129 (2007).
  • Zheng J , OchoaE, MisselwitzBet al. Targeted contrast agent helps to monitor advanced plaque during progression: a magnetic resonance imaging study in rabbits. Invest. Radiol. 43(1), 49–55 (2008).
  • Koktzoglou I , HarrisKR, TangRet al. Gadofluorine-enhanced magnetic resonance imaging of carotid atherosclerosis in Yucatan miniswine. Invest. Radiol. 41(3), 299–304 (2006).
  • Sirol M , ItskovichVV, ManiVet al. Lipid-rich atherosclerotic plaques detected by gadofluorine-enhanced in vivo magnetic resonance imaging. Circulation 109(23), 2890–2896 (2004).
  • Barkhausen J , EbertW, HeyerC, DebatinJF, WeinmannHJ. Detection of atherosclerotic plaque with gadofluorine-enhanced magnetic resonance imaging.Circulation108(5), 605–609 (2003).
  • Ronald JA , ChenJW, ChenYet al. Enzyme-sensitive magnetic resonance imaging targeting myeloperoxidase identifies active inflammation in experimental rabbit atherosclerotic plaques. Circulation 120(7), 592–599 (2009).
  • Chen JW , PhamW, WeisslederR, BogdanovA Jr. Human myeloperoxidase: a potential target for molecular MR imaging in atherosclerosis. Magn. Reson. Med.52(5), 1021–1028 (2004).
  • Querol M , BennettDG, SotakC, KangHW, BogdanovA Jr. A paramagnetic contrast agent for detecting tyrosinase activity. ChemBioChem.8(14), 1637–1641 (2007).
  • Tung CH , HoNH, ZengQet al. Novel factor XIII probes for blood coagulation imaging. ChemBioChem. 4(9), 897–899 (2003).
  • Nivorozhkin AL , KolodziejAF, CaravanP, GreenfieldMT, LaufferRB, McMurryTJ. Enzyme-activated Gd3+ magnetic resonance imaging contrast agents with a prominent receptor-induced magnetization enhancement Angew. Chem. Int. Ed. Engl.40(15), 2903–2906 (2001).
  • Louie AY , HuberMM, AhrensETet al. In vivo visualization of gene expression using magnetic resonance imaging. Nat. Biotechnol.18(3), 321–325 (2000).
  • Young JL , LibbyP, SchonbeckU. Cytokines in the pathogenesis of atherosclerosis.Thromb. Haemost.88(4), 554–567 (2002).
  • Naruko T , UedaM, HazeKet al. Neutrophil infiltration of culprit lesions in acute coronary syndromes. Circulation 106(23), 2894–2900 (2002).
  • Brennan ML , PennMS, Van Lente F et al. Prognostic value of myeloperoxidase in patients with chest pain. N. Engl. J. Med.349(17), 1595–1604 (2003).
  • Nicholls SJ , HazenSL. Myeloperoxidase and cardiovascular disease.Arterioscler. Thromb. Vasc. Biol.25(6), 1102–1111 (2005).
  • Sugiyama S , KugiyamaK, AikawaM, NakamuraS, OgawaH, LibbyP. Hypochlorous acid, a macrophage product, induces endothelial apoptosis and tissue factor expression: involvement of myeloperoxidase-mediated oxidant in plaque erosion and thrombogenesis.Arterioscler. Thromb. Vasc. Biol.24(7), 1309–1314 (2004).
  • Querol M , ChenJW, WeisslederR, BogdanovA Jr. DTPA-bisamide-based MR sensor agents for peroxidase imaging. Org. Lett.7(9), 1719–1722 (2005).
  • Chen JW , Querol Sans M, Bogdanov A Jr. Weissleder R. Imaging of myeloperoxidase in mice by using novel amplifiable paramagnetic substrates. Radiology240(2), 473–481 (2006).
  • Querol M , ChenJW, BogdanovAA Jr. A paramagnetic contrast agent with myeloperoxidase-sensing properties. Org. Biomol. Chem.4(10), 1887–1895 (2006).
  • Nahrendorf M , SosnovikD, ChenJWet al. Activatable magnetic resonance imaging agent reports myeloperoxidase activity in healing infarcts and noninvasively detects the antiinflammatory effects of atorvastatin on ischemia-reperfusion injury. Circulation 117(9), 1153–1160 (2008).
  • Yeon SB , SabirA, ClouseMet al. Delayed-enhancement cardiovascular magnetic resonance coronary artery wall imaging: comparison with multislice computed tomography and quantitative coronary angiography. J. Am. Coll. Cardiol. 50(5), 441–447 (2007).
  • Harisinghani MG , BarentszJ, HahnPFet al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N. Engl. J. Med. 348(25), 2491–2499 (2003).
  • Winter PM , NeubauerAM, CaruthersSDet al. Endothelial α-(v)-β-3 integrin-targeted fumagillin nanoparticles inhibit angiogenesis in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 26(9), 2103–2109 (2006).
  • Wehrl HF , JudenhoferMS, WiehrS, PichlerBJ. Pre-clinical PET/MR: technological advances and new perspectives in biomedical research.Eur. J. Nucl. Med. Mol. Imaging36(Suppl. 1), S56–S68 (2009).
  • Schlemmer HP , PichlerBJ, SchmandMet al. Simultaneous MR/PET imaging of the human brain: feasibility study. Radiology 248(3), 1028–1035 (2008).
  • Catana C , ProcissiD, WuYet al. Simultaneous in vivo positron emission tomography and magnetic resonance imaging. Proc. Natl Acad. Sci. USA 105(10), 3705–3710 (2008).
  • Lanza GM , WinterPM, NeubauerAM, CaruthersSD, HockettFD, WicklineSA. 1H/19F magnetic resonance molecular imaging with perfluorocarbon nanoparticles. Curr. Top. Dev. Biol.70, 57–76 (2005).
  • Merritt ME , HarrisonC, StoreyC, JeffreyFM, SherryAD, MalloyCR. Hyperpolarized 13C allows a direct measure of flux through a single enzyme-catalyzed step by NMR.Proc. Natl Acad. Sci. USA104(50), 19773–19777 (2007).
  • Olsson LE , ChaiCM, AxelssonO, KarlssonM, GolmanK, PeterssonJS. MR coronary angiography in pigs with intraarterial injections of a hyperpolarized 13C substance.Magn. Reson. Med.55(4), 731–737 (2006).
  • Sherry AD , WoodsM. Chemical exchange saturation transfer contrast agents for magnetic resonance imaging.Annu. Rev. Biomed. Eng.10, 391–411 (2008).
  • Ward KM , AletrasAH, BalabanRS. A new class of contrast agents for MRI based on proton chemical exchange dependent saturation transfer (CEST).J. Magn. Reson.143(1), 79–87 (2000).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.